UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $640

Benzinga Newsdesk www.benzinga.com Negative 80.5%

Neg 80.5% Neu 0% Pos 0%

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $730 to $640.